Kristen L Nowak1, Kristine Yaffe2, Eric S Orwoll3, Joachim H Ix4,5, Zhiying You6, Elizabeth Barrett-Connor7, Andrew R Hoffman8, Michel Chonchol6. 1. Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Kristen.Nowak@ucdenver.edu. 2. Departments of Psychiatry, Neurology, and Epidemiology, University of California San Francisco, San Francisco, California. 3. Bone and Mineral Unit, Oregon Health and Science University, Portland, Oregon. 4. Divisions of Nephrology and Preventative Medicine, University of California San Diego, San Diego, California. 5. Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California. 6. Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 7. Division of Epidemiology, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California; and. 8. Division of Endocrinology, Gerontology and Metabolism, Stanford University, Stanford, California.
Abstract
BACKGROUND AND OBJECTIVES: Mild hyponatremia is a common finding in older adults; however, the association of lower serum sodium with cognition in older adults is currently unknown. We determined whether lower normal serum sodium is associated with cognitive impairment and risk of cognitive decline in community-dwelling older men. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five thousand four hundred thirty-five community-dwelling men aged ≥65 years who participated in Osteoporotic Fractures in Men, a cohort study with a median follow-up for cognitive function of 4.6 years, were included in this analysis. Multivariable logistic regression was used to examine the association between baseline fasting serum sodium levels and the odds of prevalent cognitive impairment (cross-sectional analysis; modified Mini-Mental Status [3MS] score <1.5 SD [<84] below or Trail Making Test Part B time >1.5 SD above the mean [>223 seconds]) and cognitive decline (prospective analysis [n=3611]; decrease in follow-up 3MS score or increase in Trails B time >1.5 SD of the mean score/time change [>9 or >67 seconds]). RESULTS: Participants were aged 74±6 years with a fasting mean serum sodium level of 141±3 mmol/L. Fifteen percent (n=274), 12% (n=225), and 13% (n=242) had prevalent cognitive impairment in tertiles 1, 2, and 3, respectively. After adjustment, lower serum sodium was associated with prevalent cognitive impairment (tertile 1 [126-140 mmol/L] versus tertile 2 [141-142 mmol/L], odds ratio [OR], 1.30; 95% confidence interval [95% CI], 1.06 to 1.61). Fourteen percent (n=159), 10% (n=125), and 13% (n=159) had cognitive decline in tertiles 1, 2, and 3, respectively. Lower serum sodium was also associated with cognitive decline (tertile 1 versus tertile 2, OR, 1.37; 95% CI, 1.06 to 1.77). Tertile 3 (143-153 mmol/L) was additionally associated with cognitive decline. Results were similar in sensitivity analyses according to clinical cut-offs and by quartiles. CONCLUSIONS: In community-dwelling older men, serum sodium between 126-140, and 126-140 or 143-153 mmol/L, are independently associated with prevalent cognitive impairment and cognitive decline, respectively.
BACKGROUND AND OBJECTIVES: Mild hyponatremia is a common finding in older adults; however, the association of lower serum sodium with cognition in older adults is currently unknown. We determined whether lower normal serum sodium is associated with cognitive impairment and risk of cognitive decline in community-dwelling older men. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five thousand four hundred thirty-five community-dwelling men aged ≥65 years who participated in Osteoporotic Fractures in Men, a cohort study with a median follow-up for cognitive function of 4.6 years, were included in this analysis. Multivariable logistic regression was used to examine the association between baseline fasting serum sodium levels and the odds of prevalent cognitive impairment (cross-sectional analysis; modified Mini-Mental Status [3MS] score <1.5 SD [<84] below or Trail Making Test Part B time >1.5 SD above the mean [>223 seconds]) and cognitive decline (prospective analysis [n=3611]; decrease in follow-up 3MS score or increase in Trails B time >1.5 SD of the mean score/time change [>9 or >67 seconds]). RESULTS:Participants were aged 74±6 years with a fasting mean serum sodium level of 141±3 mmol/L. Fifteen percent (n=274), 12% (n=225), and 13% (n=242) had prevalent cognitive impairment in tertiles 1, 2, and 3, respectively. After adjustment, lower serum sodium was associated with prevalent cognitive impairment (tertile 1 [126-140 mmol/L] versus tertile 2 [141-142 mmol/L], odds ratio [OR], 1.30; 95% confidence interval [95% CI], 1.06 to 1.61). Fourteen percent (n=159), 10% (n=125), and 13% (n=159) had cognitive decline in tertiles 1, 2, and 3, respectively. Lower serum sodium was also associated with cognitive decline (tertile 1 versus tertile 2, OR, 1.37; 95% CI, 1.06 to 1.77). Tertile 3 (143-153 mmol/L) was additionally associated with cognitive decline. Results were similar in sensitivity analyses according to clinical cut-offs and by quartiles. CONCLUSIONS: In community-dwelling older men, serum sodium between 126-140, and 126-140 or 143-153 mmol/L, are independently associated with prevalent cognitive impairment and cognitive decline, respectively.
Authors: Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone Journal: Contemp Clin Trials Date: 2005-10 Impact factor: 2.226
Authors: Cora E Lewis; Susan K Ewing; Brent C Taylor; James M Shikany; Howard A Fink; Kristine E Ensrud; Elizabeth Barrett-Connor; Steven R Cummings; Eric Orwoll Journal: J Bone Miner Res Date: 2007-02 Impact factor: 6.741
Authors: Nicola Napoli; Elsa S Strotmeyer; Kristine E Ensrud; Deborah E Sellmeyer; Douglas C Bauer; Andrew R Hoffman; Thuy-Tien L Dam; Elizabeth Barrett-Connor; Lisa Palermo; Eric S Orwoll; Steven R Cummings; Dennis M Black; Ann V Schwartz Journal: Diabetologia Date: 2014-06-09 Impact factor: 10.122
Authors: Ewout J Hoorn; Fernando Rivadeneira; Joyce B J van Meurs; Gijsbertus Ziere; Bruno H Ch Stricker; Albert Hofman; Huibert A P Pols; Robert Zietse; André G Uitterlinden; M Carola Zillikens Journal: J Bone Miner Res Date: 2011-08 Impact factor: 6.741
Authors: Manal Mazloum; Jordan Jouffroy; François Brazier; Christophe Legendre; Antoine Neuraz; Nicolas Garcelon; Dominique Prié; Dany Anglicheau; Frank Bienaimé Journal: J Am Soc Nephrol Date: 2019-06-19 Impact factor: 10.121
Authors: Kristen L Nowak; Michel Chonchol; Anna Jovanovich; Zhiying You; Jeffrey Bates; Capri Foy; Stephen Glasser; Anthony A Killeen; John Kostis; Carlos J Rodriguez; Mark Segal; Debra L Simmons; Addison Taylor; Laura C Lovato; Walter T Ambrosius; Mark A Supiano Journal: Am J Hypertens Date: 2019-06-11 Impact factor: 2.689
Authors: George D Daniel; Haiying Chen; Alain G Bertoni; Stephen R Rapp; Annette L Fitzpatrick; José A Luchsinger; Alexis C Wood; Timothy M Hughes; Gregory L Burke; Kathleen M Hayden Journal: Clin Nutr ESPEN Date: 2021-10-11
Authors: Julie Martin-Grace; Maria Tomkins; Michael W O'Reilly; Chris J Thompson; Mark Sherlock Journal: J Clin Endocrinol Metab Date: 2022-07-14 Impact factor: 6.134
Authors: Paul Thomas Brinkkoetter; Franziska Grundmann; Panteha Jazayeri Ghassabeh; Ingrid Becker; Marc Johnsen; Victor Suaréz; Ralf-Joachim Schulz; Thomas Streichert; Volker Burst Journal: Sci Rep Date: 2019-08-29 Impact factor: 4.379